Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy

DEMİRCAN, NAZIM; DANE, FAYSAL; Ozturk, Mehmet; Babacan, Nalan; Besiroglu, Mehmet; Kaya, Serap; Ercelep, Ozlem; Tanrikulu, Eda; Halil, Suleyman; Koca, Sinan; Alan, Ozkan; Hasano, Rahip; YUMUK, PERRAN

Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy

Atıf İçin Kopyala

DEMİRCAN N. C., DANE F., Ozturk M. A., Babacan N. A., Besiroglu M., Kaya S., ...Daha Fazla

JOURNAL OF BUON, cilt.24, sa.4, ss.1494-1500, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 4
Basım Tarihi: 2019
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1494-1500
Anahtar Kelimeler: bevacizumab, colorectal cancer, prognostic factors, PRIMARY TUMOR RESECTION, K-RAS MUTATION, COLON-CANCER, CURATIVE RESECTION, PHASE-III, FOLLOW-UP, STAGE, CHEMOTHERAPY, OUTCOMES, TRIAL
Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Colorectal cancer (CRC) is a significant cause of cancer mortality worldwide. Survival has improved with bevacizumab in metastatic CRC treatment. Our purpose was to analyse survival and prognostic factors in metastatic CRC patients treated with first-line bevacizumab-based treatment.